Heart Test Laboratories, Inc. (HSCS), a Texas-based medical technology company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for the potential sale of up to 34,684,859 shares of its common stock. The shares include those previously issued to certain selling stockholders and those that may be issued to Lincoln Park Capital Fund, LLC pursuant to a purchase agreement. The company will not receive proceeds from the selling stockholders' shares, except for any proceeds from the exercise of warrants. However, proceeds from the sale of shares to Lincoln Park will be used for working capital and general corporate purposes. The shares are being offered through a prospectus, and the offering will be made only by means of the prospectus. The registration statement includes details about the company's financials, risks, and the terms of the offering. The shares of common stock are listed on the Nasdaq Capital Market under the symbol 'HSCS'.

Heart Test Laboratories, Inc. (HSCS), a Texas-based medical technology company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for the potential sale of up to 34,684,859 shares of its common stock. The shares include those previously issued to certain selling stockholders and those that may be issued to Lincoln Park Capital Fund, LLC pursuant to a purchase agreement. The company will not receive proceeds from the selling stockholders' shares, except for any proceeds from the exercise of warrants. However, proceeds from the sale of shares to Lincoln Park will be used for working capital and general corporate purposes. The shares are being offered through a prospectus, and the offering will be made only by means of the prospectus. The registration statement includes details about the company's financials, risks, and the terms of the offering. The shares of common stock are listed on the Nasdaq Capital Market under the symbol 'HSCS'.